The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.
 
Yayoi Ando
No Relationships to Disclose
 
Tatsunori Shimoi
No Relationships to Disclose
 
Kuniko Sunami
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Illumina; Konica Minolta Precision Medicine; Lilly; Novartis; Pfizer; Riken Genesis; Sysmex
Research Funding - Sysmex
 
Natsuko Tsuda Okita
No Relationships to Disclose
 
Mikio Mori
Employment - QOL Medical LLC (I)
Stock and Other Ownership Interests - Daiichi Sankyo
 
Taro Shibata
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; IQvia; Lilly; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Ono Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)